Back to chapter

3.7:

Bioequivalence: Overview

JoVE Core
Pharmacology
Bu içeriği görüntülemek için JoVE aboneliği gereklidir.  Oturum açın veya ücretsiz deneme sürümünü başlatın.
JoVE Core Pharmacology
Bioequivalence: Overview

Diller

Paylaş

Two drug products containing the same active ingredient in the same amounts, dosage forms, and routes of administration are considered pharmaceutical equivalents. Pharmaceutical equivalents are considered bioequivalent if the bioavailability of the active moiety in the drug preparations is comparable. Pharmaceutical equivalents that exhibit bioequivalence are also therapeutically equivalent if, when administered as directed, the drugs possess the same clinical effect and safety profile. For clinical efficacy, the maximum drug concentration and the time required to reach the peak concentration must fall within the acceptable limit. Sometimes, the bioavailability of a drug's dosage form may vary between manufacturers or batches from a single manufacturer. Poor control of differences in various physical characteristics of a drug during formulation and manufacturing influences how the drug disintegrates and dissolves, which affects the drug's bioavailability. If a generic drug is to be approved, its bioequivalence profile must be comparable to the reference product.

3.7:

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed, they yield the same clinical effect and safety profile.

A key determinant of clinical effectiveness is that the peak concentration of the drug, and the time taken to achieve this peak concentration, must fall within an acceptable range. However, there can be variations in the bioavailability of a drug's dosage form. These discrepancies might occur between different manufacturers or even among different batches from the same manufacturer. The reason behind this is often inadequate control over the drug's physical properties during its formulation and manufacturing. This lack of control can affect how the drug disintegrates and dissolves, impacting its bioavailability. Finally, for a generic drug to gain approval, its bioequivalence profile must align closely with that of the reference product.